ATM and ovarian carcinoma: Approved (FDA) as single agent since 2016 in advanced BRCA mutated/HRD ovarian cancer BRCA mutated mCRPC (2020).Phase III as single agent in ovarian cancer, BRCA or ATM mutated mCRPC. In combination with nivolumab in ovarian cancer, with enzalutamide in mCRPC